Previous 10 | Next 10 |
Abeona Therapeutics Inc. (ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 am ET Company Participants Vishwas Seshadri - Chief Executive Officer Joseph Vazzano - Chief Financial Officer Brian Kevany - Chief Technical Officer, Head of Research Greg Gin - Vice President, Investor Relati...
Ultragenyx Pharmaceutical (NASDAQ:RARE) is acquiring global rights to Abeona Therapeutics' (NASDAQ:ABEO) AAV gene therapy ABO-102 (now UX111) to treat Sanfilippo syndrome type A (MPS IIIA). Sanfilippo syndrome is a rare, fatal genetic condition that causes brain degeneration, and ca...
ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today NOVATO, Calif. and NEW YORK and CLEVELAND, May 17, 2022 (GLOBE N...
Abeona Therapeutics press release (NASDAQ:ABEO): Q1 GAAP EPS of -$0.14 misses by $0.04. Revenue of $0.35M. Cash, cash equivalents, restricted cash and short-term investments totaled $37.2 million as of March 31, 2022. Shares +0.57% PM For further details see: Abeona Therapeutics GAAP EP...
Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023 Focus R&D resources on EB-101 pivotal phase 3 VIITAL™ topline data expected in 3Q 2022 NEW YORK and CLEVELAND, May 13, 2022 (GLOBE NEWSWIRE) -- Abeona ...
NEW YORK and CLEVELAND, Ohio, May 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced the presentation of new preclinical data on AAV204 at the Association for Research and Vision in Ophthalmology (ARVO) A...
NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on AAV204, a novel adeno-associated virus (AAV) capsid from Abeona’s in-licensed AIM™ c...
Abeona Therapeutics (NASDAQ:ABEO) entered into a securities purchase agreement with certain institutional investors to purchase 1M shares of Series A convertible redeemable preferred stock and 250,005 shares of Series B convertible redeemable preferred stock. Each share of Series A and S...
NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,000,006 shares ...
Abeona Therapeutics press release (NASDAQ:ABEO): FY GAAP EPS of -$0.45 beats by $0.15. Revenue of $3M (flat Y/Y). Cash, cash equivalents, restricted cash and short-term investments totaled $50.9 million as of December 31, 2021, compared to $96.0 million as of December 31, 2020 Shares +2.74% P...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...